Compare DexCom, Inc. (DXCM) vs PubMatic Inc (PUBM) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

PUBM stock trades at $13.62, down 0.51% on the day, with a mixed technical picture showing a bullish moving average signal but a neutral oscillator stance. The company reported a net loss of -$14.46M for 2025 despite beating EPS estimates in recent quarters, with revenue of $282.93M. Positive news includes new product launches like AgenticOS and a Creator Marketplace, alongside a balanced analyst consensus of 8 Buy and 8 Hold ratings.

The outlook is cautiously optimistic, supported by strong operating cash flow of $81.06M and a consensus price target of $17.00, implying potential upside. Key risks include sustained negative profit margins and competitive pressures in the ad tech sector. Investor sentiment is buoyed by recent strategic partnerships and AI-driven growth initiatives, though profitability remains a critical watchpoint.